Atropine IV Administration Protocol
For symptomatic bradycardia, the recommended dose of atropine is 0.5-1 mg IV, repeated every 3-5 minutes as needed to a maximum total dose of 3 mg. 1, 2
Dosing Guidelines by Indication
Symptomatic Bradycardia
- Initial dose: 0.5-1 mg IV 2, 1
- Repeat: Every 3-5 minutes if needed 2
- Maximum total dose: 3 mg 1
- Peak action: Within 3 minutes of IV administration 2
Asystole/Cardiac Arrest
- Initial dose: 1 mg IV 2
- Repeat: Every 3-5 minutes if asystole persists (while CPR continues) 2
- Maximum total dose: 3 mg (or 0.04 mg/kg) 1, 3
Special Populations
- Patients with coronary artery disease: Limit total dose to 0.03-0.04 mg/kg to minimize risk of tachycardia-induced ischemia 3, 4
- Pediatric patients: 0.01-0.03 mg/kg IV 3
Administration Technique
- Administer as IV push
- Inspect solution for clarity and particulate matter before administration 3
- Use single-dose vial; discard unused portion 3
- Titrate based on heart rate, PR interval, blood pressure, and symptoms 3
Important Precautions
Minimum Effective Dose
- CAUTION: Doses less than 0.5 mg may cause paradoxical bradycardia due to central vagal stimulation 2, 1
Monitoring Requirements
- Continuous ECG monitoring during and after administration
- Monitor blood pressure and heart rate response
- Observe for signs of increased ischemia in patients with coronary artery disease 2, 4
Potential Adverse Effects
- Tachycardia (may increase myocardial oxygen demand)
- Dry mouth, blurred vision
- Ventricular arrhythmias (rare but serious) 2, 1
- Central nervous system effects with repeated doses (hallucinations, fever) 2
Specific Clinical Scenarios
Class I Indications (ACC/AHA) 2
- Sinus bradycardia with evidence of low cardiac output and peripheral hypoperfusion
- Acute inferior infarction with symptomatic type I second-degree AV block
- Bradycardia and hypotension after nitroglycerin administration
- Asystole
Not Recommended For
- Asymptomatic bradycardia (heart rate >40 bpm) 2
- Type II second-degree AV block 2
- Third-degree AV block with new wide QRS complex 2
Storage and Stability
- Commercially available as 0.4 mg/mL or 1 mg/mL solutions 3, 5
- If compounded from powder, refrigerate if not used within 28 days 5
By following these evidence-based guidelines for atropine administration, clinicians can effectively manage symptomatic bradycardia while minimizing potential adverse effects and optimizing patient outcomes.